Skip to main content

Newsroom press releases

06/05/25 - 17:41

Revenue growing +8% and EBITDA margin at 34%: Q1 Results confirm FY 2025 Guidance (268.56 KB)
Financial Data

28/04/25 - 16:50

Shareholders' Meeting 2025 (138.81 KB)
Other

18/04/25 - 18:11

Diasorin receives 510(k) clearance for its second multiplex molecular panel for diagnosing bloodstream infections on LIAISON PLEX® (161.29 KB)
Products

07/04/25 - 13:07

Publication of the lists of candidates for the appointment of the Board Directors, the Board of Statutory Auditors and relevant proposals for resolution. (111.09 KB)
Financial Disclosures

04/04/25 - 0:59

Notice pursuant to art. 144-octied, para. 2 of CONSOB regulation No. 1971/1999 (125.78 KB)
Other

31/03/25 - 19:36

Adoption of the enhancement of the increased voting rights mechanism: withdrawal exercised by 1.69% of the share capital. Statutory option and pre-emption offer period to start on 31 March 2025. (119.78 KB)
Other

18/03/25 - 11:54

Diasorin launches the Simplexa™ C. auris direct assay on the LIAISON® MDX instrument in all countries accepting the CE Mark (126.65 KB)
Products Molecular

14/03/25 - 16:29

The Board of Directors of Diasorin SpA approves FY2024 Results with revenues and net profit in expansion compared to Previous Year; Proposed Ordinary Dividend of € 1.20 per share (239.79 KB)
Financial Data

03/03/25 - 21:19

Registration and publication the minutes of shareholders' meeting. Withdrawal right. (101.04 KB)
Other

03/03/25 - 21:05

Notice to Shareholders - Information regarding the exercise of the withdrawal right (88.54 KB)
Other

28/02/25 - 11:49

The Extraordinary Meeting of Shareholders approves the enhancement of the increased voting rights mechanism (111.6 KB)
Other

27/01/25 - 20:14

Proposal to enhance the increased voting rights mechanism to support the Company's growth strategy, also by external lines, and reward a shareholder base with a long-term investment horizon (126.5 KB)
Other

11/11/15 - 1:00

The Board of Directors approves the results for Q3'15 (778.06 KB)
Financial Data

09/09/15 - 2:00

DiaSorin launches the two fastest molecular diagnostic tests in the world to detect fulminant leukemias (229.24 KB)
Products Molecular

30/07/15 - 2:00

H1'15 Results (777.06 KB)
Financial Data

20/07/15 - 2:00

DiaSorin and Beckman Coulter sign a distribution agreement for China (238.01 KB)
Acquisition / Partnership

28/05/15 - 2:00

DiaSorin launches the test for Campylobacter (241.86 KB)
Products Immunodiagnostic

12/05/15 - 2:00

The Board of Directors approves the results for Q1'15 (553.96 KB)
Financial Data

12/05/15 - 2:00

DiaSorin presents the 2015-2017 industrial plan (305.81 KB)
Other

29/04/15 - 2:00

DiaSorin - launches the test for Brahms-Sepsis (506.96 KB)
Products Immunodiagnostic

23/04/15 - 2:00

DiaSorin supports the Pinocchio Project (251.16 KB)

22/04/15 - 2:00

The Board of Directors approves the 2015-2017 plan that will be presented at the Investor Day (141.85 KB)
Financial Data

22/04/15 - 2:00

Shareholders' meeting approves FY Results 2014 (105.93 KB)
Financial Data

14/04/15 - 2:00

DiaSorin launches the tests for Bordetella pertussis (187.11 KB)
Products Immunodiagnostic

10/04/15 - 2:00

Investor Day-save the date (107.93 KB)
Financial Data

24/03/15 - 1:00

DiaSorin in aid of Haiti's children in partnership with the Francesca Rava Foundation (504.27 KB)

03/03/15 - 1:00

The Board of Directors approves the results for FY'14 (783.03 KB)
Financial Data

24/02/15 - 1:00

DiaSorin supports Emergency in Sudan (612.64 KB)

13/02/15 - 1:00

DiaSorin teams with FISIP for Progetto talenti (612.64 KB)

14/01/15 - 1:00

DiaSorin launches the test for Calprotectin (259.67 KB)
Products Immunodiagnostic